Rosalind Advisors’s aTyr Pharma ATYR Stock Holding History

Rosalind Advisors’s Portfolio ATYR Stock Details ATYR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,039,080	Closed	-$13.6M	–	50
2025 Q4	$13.6M	Hold	1,039,080	–	–	4.78%	9
2025 Q3	$7.56M	Buy	+1,039,080	New	+$4.71M	2.59%	18

Other funds holding ATYR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Rosalind Advisors's ATYR Position: Q1 2026 in Review

Rosalind Advisors sold out of aTyr Pharma (ATYR) in Q1 2026, closing a stake of 1,039,080 shares — an estimated $13.6M sold.

Rosalind Advisors first reported a position in ATYR in Q3 2025 and held it in 2 quarters. The position peaked at $13.6M in Q4 2025. 111 funds tracked by Wall St. Rank hold ATYR as of Q1 2026.

Rosalind Advisors reported no remaining aTyr Pharma position as of Q1 2026 after selling out during the quarter.
Rosalind Advisors sold 1,039,080 aTyr Pharma shares in Q1 2026, an estimated $13.6M.
Rosalind Advisors first reported a position in aTyr Pharma in Q3 2025 and held it in 2 quarters.
Rosalind Advisors's aTyr Pharma position peaked at $13.6M in Q4 2025.
111 funds tracked by Wall St. Rank held aTyr Pharma as of Q1 2026.

Based on Rosalind Advisors's 13F filing for Q1 2026, filed 14 May 2026.